Status:
COMPLETED
Convalescent Plasma for the Treatment of Patients With WNV - a Double- Blind Randomized Controlled Study
Lead Sponsor:
Sheba Medical Center
Conditions:
West Nile Fever With Neurologic Manifestation (Diagnosis)
West Nile Fever Without Complications
Eligibility:
All Genders
18+ years
Phase:
PHASE3
Brief Summary
Name of the study: Administering neutralizing convalescent plasma to hospitalized patients with West Nile fever - a double-blind randomized controlled study. The purpose of this study is to test the...
Detailed Description
The study is performed in Sheba Medical Center ( and will be expanded in the soon future to other Medical centers in Israel). Hospitalized patients diagnosed by blood/CSF PCR or IgM, with West Nile V...
Eligibility Criteria
Inclusion
- Hospitalized patients with positive WNV-PCR with fever/neurological symptoms, and 72 hours have not yet passed since the positive result.
- Age 60 or older.
- Age over 18 and younger than 60 with immunosuppression (hypogammaglobulinemia, solid organ transplants, bone marrow transplants, hemato-oncological malignancies).
Exclusion
- Age younger than 60 without immunosuppression.
- More than 72 hours have passed since the diagnosis of West Nile fever.
- Pregnant women. Criteria for exclusion from the experiment: none Reference to the inclusion of pregnant women, special populations - children and those lacking judgment- not relevant: excludes pregnant women and special populations
Key Trial Info
Start Date :
July 4 2024
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
March 30 2025
Estimated Enrollment :
200 Patients enrolled
Trial Details
Trial ID
NCT06590207
Start Date
July 4 2024
End Date
March 30 2025
Last Update
April 29 2025
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Sheba Medical Center
Ramat Gan, Israel, Israel, 5265601